Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
82,878
Stocks News & Analysis
stocks
Earnings Winners: BHP, NAB & TLS lead the pack
The winners of this weeks earnings that saw strong investor backing
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
We think Walmart stock is significantly overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,303.20 | 9.30 | 0.10% |
| CAC 40 | 8,463.57 | 64.79 | 0.77% |
| DAX 40 | 25,092.19 | 48.62 | 0.19% |
| Dow JONES (US) | 49,395.16 | 267.50 | -0.54% |
| FTSE 100 | 10,677.10 | 50.06 | 0.47% |
| HKSE | 26,413.35 | 292.59 | -1.10% |
| NASDAQ | 22,682.73 | 70.91 | -0.31% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,308.52 | 135.68 | -1.01% |
| S&P 500 | 6,861.89 | 19.42 | -0.28% |
| S&P/ASX 200 | 9,081.40 | 17.00 | 0.19% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |